Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.

According to the above studies, a decreasing trend in BTMs has been observed since the early months of treatment with denosumab, indicating that such markers can be used for the early evaluation of effectiveness, and this trend has continued for up to 36 months, which is in accordance with the results of the present study.

also in 47,180 other papers